Leukaemia Section
Short Communication

\( t(1;21)(p35;q22) \)
Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: September 2007
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0121p35q22ID1447.html
DOI: 10.4267/2042/38583

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

**Clinics and pathology**

**Disease**
Acute myeloid leukaemia (AML)

**Epidemiology**
Only one case to date, a 68-year-old male patient with M2 AML.

**Prognosis**
No data.

**Genes involved and Proteins**

**YTHDF2**
Location: 1p35
Protein
Possible role in immune response.

**RUNX1**
Location: 21q22
Protein
Transcription factor (activator) for various hematopoietic-specific genes, which expression is limited to hematopoietic stem cells, and endothelial cells and mesenchymal cells in the embryo; core binding factor family member which forms heterodimers with CBFB; binds to the core site 5' PyGPyGGTPy 3' of promoters and enhancers.

**Results of the chromosomal anomaly**

**Hybrid gene**
Description
5' RUNX1- 3' YTHDF2

**References**
Nguyen TT, Ma LN, Slovak ML, Bangs CD, Cherry AM, Arber DA. Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDF2, and ZNF687 in acute myeloid leukemia. Genes Chromosomes Cancer 2006;45:918-932.

This article should be referenced as such: